Summary
Definition
History and exam
Key diagnostic factors
- presencia de factores de riesgo
- despigmentación de la piel de la zona acral y perioral
- despigmentación de la piel de la zona perianal y genital
- traumatismo cutáneo reciente
- dolor localizado por quemadura solar
- realce y fluorescencia con exposición a radiación UVA
- nevo con halo
- despigmentación universal
Risk factors
- edad <30 años
- antecedentes familiares de vitiligo
- enfermedad autoinmune
- contacto químico
Diagnostic tests
1st tests to order
- diagnóstico clínico
Tests to consider
- Examen con lámpara de Wood
- biopsia de piel
Treatment algorithm
vitiligo segmentario o vitiligo limitado
vitiligo generalizado (más del 3% del área de superficie corporal)
Contributors
Authors
John E. Harris, MD, PhD
Professor
Department of Dermatology
University of Massachusetts Medical School
Worcester
MA
Disclosures
JEH has acted as a consultant and/or investigator for: Pfizer, Genzyme/Sanofi, Aclaris Therapeutics Inc., Incyte, Rheos Medicines, Sun Pharmaceuticals, LEO Pharma, Villaris Therapeutics Inc., Dermavant, Temprian, AbbVie Inc., Janssen, TeVido, BioDevices, EMD Serono, Almirall, Boston Pharma, Sonoma Biotherapeutics Inc., Methuselah Health, Twi Biotech, Pandion, Cogen Therapeutics Inc., Admirx, BridgeBio, AnaptysBio, Avita, Frazier Management. He has equity in TeVido Biodevices, Rheos, and Villaris Therapeutics Inc., and is the Scientific Founder of Villaris Therapeutics Inc. JEH is an author of a number of references cited in this topic.
Mehdi Rashighi, MD
Assistant Professor
Department of Dermatology
University of Massachusetts Medical School
Worcester
MA
Disclosures
MR has received consulting fees and/or research grants from the following: Pfizer, AbbVie, Dermavant, LEO Pharma, and Almirall. MR is an author of a reference cited in this topic.
Acknowledgements
Professor John E. Harris and Dr Mehdi Rashighi would like to gratefully acknowledge Dr Bernhard Ortel, a previous contributor to this topic. BO declares that he has no competing interests.
Peer reviewers
Iltefat Hamzavi, MD
Senior Staff Physician
Multicultural Dermatology Center
Henry Ford Hospital
Detroit
MI
გაფრთხილება:
IH is an author of a number of references cited in this topic.
Piergiacomo Calzavara-Pinton, MD
Chair
Dermatology Department
University of Brescia
Brescia
Italy
გაფრთხილება:
PC-P is an author of a number of references cited in this topic.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
წყაროები
ძირითადი სტატიები
Ortonne J-P. Vitiligo and other disorders of hypopigmentation. In: Bolognia JL, Jorrizzo JL, Rapini RP, eds. Dermatology. New York, NY: Mosby; 2008:913-38.
Taieb A, Picardo M. Clinical practice: vitiligo. N Engl J Med. 2009 Jan 8;360(2):160-9. აბსტრაქტი
Taieb A, Alomar A, Böhm M, et al; Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Européenne des Médecins Spécialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013 Jan;168(1):5-19.სრული ტექსტი აბსტრაქტი
Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2015 Feb 24;(2):CD003263.სრული ტექსტი აბსტრაქტი
გამოყენებული სტატიები
ამ თემაში მოხსენიებული წყაროების სრული სია ხელმისაწვდომია მომხმარებლებისთვის, რომლებსაც აქვთ წვდომა BMJ Best Practice-ის ყველა ნაწილზე.
დიფერენციული დიაგნოზები
- Piebaldismo
- Síndrome de Waardenburg
- Esclerosis tuberosa
მეტი დიფერენციული დიაგნოზებიგაიდლაინები
- British Association of Dermatologists guidelines for the management of people with vitiligo 2021
- Guidelines for the management of vitiligo
მეტი გაიდლაინები
შედით სისტემაში ან გამოიწერეთ BMJ Best Practice
ამ მასალის გამოყენება ექვემდებარება ჩვენს განცხადებას